Loading...

Channel Therapeutics Corporation

PTHS•NYSE
Healthcare
Biotechnology
$26.48
$10.01(60.78%)

Channel Therapeutics Corporation (PTHS) Stock Overview

Explore Channel Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap16.6M
P/E RatioN/A
EPS (TTM)N/A
ROEN/A
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

PTHS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Channel Therapeutics Corporation (PTHS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 16.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PTHSStats details for PTHS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PTHSAnalyst Recommendations details for PTHS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Clinical-stage biopharma focused on ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum, plus NaV1.7 pain pipeline. Resulted from merger of Channel Therapeutics with Ligand’s LNHC/Pelthos.

Headquarters

4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703, Durham, NC

Founded

2025

Frequently Asked Questions

;